Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.
- Citation:
- Int J Radiat Oncol Biol Phys vol 67 (4) 995-1001
- Year:
- 2007
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- CA-37404, CA-35431, CA35103, CA-52352, CA-35195, U10 CA037404, U10 CA035195, CA-25224, CA-60276, CA-35113, U10 CA035431, UG1 CA189808, CA-35101, U10 CA025224, CA-63849
- Corr. Author:
- Authors:
- Yolanda I Garces Scott H Okuno Steven E Schild Sumithra J Mandrekar Brian M Bot John M Martens Donald B Wender Gamini S Soori Dennis F Moore Timothy F Kozelsky James R Jett
- Networks:
- Study
- NCCTG-N9923
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 1/2
- Keywords:
- Adult, Aged, Amifostine, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Small Cell, Cisplatin, Combined Modality Therapy, Cranial Irradiation, Etoposide, Female, Humans, Lung Neoplasms, Male, Middle Aged, Paclitaxel, Quality Control, Quality of Life, Radiation-Sensitizing Agents, Radiotherapy Dosage, Topotecan